Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02695121 · ClinicalTrials.gov registry record
Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment
A clinical trial of Breast Cancer and Bladder Cancer, sponsored by AstraZeneca.
- Completed
- Registry status
- 2,133,575
- Enrollment target
- 4
- Study locations
NCT02695121: Completed study of Breast Cancer and Bladder Cancer, sponsored by AstraZeneca.
NCT02695121 is a study of Breast Cancer and Bladder Cancer that has completed, run by AstraZeneca. The registered enrollment target is 2,133,575 participants, above the 1,060-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (201181% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02695121, a study of Breast Cancer and Bladder Cancer, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 2,133,575 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objectives of this study are (1) to compare the incidence of breast cancer, by insulin use at cohort entry, among females with type 2 diabetes who are new users of dapagliflozin and females who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2 (SGLT2) inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy and (2) to compare the incidence of bladder cancer, by insulin use at the index date and by pioglitazone use at the index date, among male and female patients with type 2 diabetes who are new users of dapagliflozin and those who are new users of ADs in classes other than SGLT2 inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy. Secondary objectives will compare, by insulin use at cohort entry, frequency of several measures of health care use, baseline characteristics, and incidence of selected other cancers in males and females between the two exposure cohorts.
Primary Outcome
Patients will be followed from their index date (date of first study drug prescription or dispensing) until the earliest of occurrence of one of the following: first occurrence of any one of the study endpoints, death, addition of a non-dapagliflozin SGLT2 inhibitor, disenrollment from the study database or transfer out of the GP practice, or end of the study period up to twelve years.
Conditions Studied
Study Locations (4)
Other
- Research Site - Utrecht
- Research Site - London
Delaware
- Research Site - Wilmington
District of Columbia
- Research Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,133,575 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2025-01-30 |
What the finished NCT02695121 record still lists
NCT02695121 is an observational study that tracks outcomes without assigning an intervention. Its 2,133,575 participants enrollment target places it among the larger protocols in the corpus, above the 1,060-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (201181% higher).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02695121 reports a single indexed study location in Other, Delaware, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02695121 about?
NCT02695121 is a clinical study titled "Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment". The primary objectives of this study are (1) to compare the incidence of breast cancer, by insulin use at cohort entry, among females with type 2 diabetes who are new users of dapagliflozin and females who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2...
What is the current status of trial NCT02695121?
This trial is currently completed. The enrollment target is 2,133,575 participants. The study started on 2017-01-01. Estimated completion is 2025-01-30.
What conditions does trial NCT02695121 study?
This clinical trial studies the following conditions: Breast Cancer, Bladder Cancer.
Who is sponsoring clinical trial NCT02695121?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02695121 being conducted?
This trial has 4 study locations across Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02695121's enrollment target sits among peer trials
2,133,575 1st of 1224 higher than 1,224 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03813862 · 2,000,000 participants
Observational Pharmaco-Epidemiology Research & Analysis
- NCT06057181 · 2,000,000 participants
Helix Research Network
- NCT06803498 · 3,000,000 participants
Delivery Room Intervention and Evaluation Network
- NCT07022951 · 1,200,000 participants
The Million Anesthesia Cases Study (MACS) - a Cohort Study of Preoperative Fasting and Perioperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI